Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Emerging concepts in intestinal immune control of obesity-related metabolic disease

Abstract

The intestinal immune system is an important modulator of glucose homeostasis and obesity-associated insulin resistance. Dietary factors, the intestinal microbiota and their metabolites shape intestinal immunity during obesity. The intestinal immune system in turn affects processes such as intestinal permeability, immune cell trafficking, and intestinal hormone availability, impacting systemic insulin resistance. Understanding these pathways might identify mechanisms underlying treatments for insulin resistance, such as metformin and bariatric surgery, or aid in developing new therapies and vaccination approaches. Here, we highlight evolving concepts centered on intestinal immunity, diet, and the microbiota to provide a working model of obesity-related metabolic disease.

Introduction

Human obesity is an excessive accumulation of adipose tissue (adiposity) clinically defined by the World Health Organization as constituting a body mass index (BMI) > 30 kg/m2 1. Obesity can be considered a growing epidemic that is associated with complications, including hyperglycemia, insulin resistance, and dyslipidemia, collectively referred to as metabolic syndrome1. Metabolic syndrome is a state of low-grade inflammation that supports the development of chronic diseases such as type 2 diabetes (T2D) mellitus, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease (CVD). In mice, aspects of metabolic syndrome are often modeled using high-fat diet feeding, in which 40~60% of caloric intake is acquired from dietary fat, resulting in the development of diet-induced obesity and associated metabolic defects, such as insulin resistance, and accompanying low-grade inflammation2.

Identifying the root cause of this low-grade inflammation is a developing avenue of research. Both adaptive and innate immune cell-mediated inflammation can occur in metabolic tissues, such as visceral adipose tissue (VAT) and the liver of individuals who are obese3,4. The intestines also display alterations in immune composition during obesity and function as a focal point of crosstalk between intestinal barrier function and intestinal microbiota5. Obesity is not only associated with a change in the composition of intestinal immune cells but also immune cell-secreted factors that shape the intestinal microbial composition, such as bacteria-specific antibodies6,7. In turn, a dysbiotic microbiome is an important factor linking the immune system with obesity-associated disease outcomes8. Moreover, a role for intestinal immune cells in controlling intestinal hormone bioavailability has been uncovered, expanding the physiological function of the immune system in endocrine regulation9. These exciting findings have pushed the field forward and highlight many current questions. Specifically, how do the intestinal immune system and microbiota regulate one another? What consequences does this crosstalk have for the development of obesity-associated metabolic disease? Do existing therapies for insulin resistance target these axes, and can we use our understanding of intestinal immune microbial crosstalk to develop new therapeutic strategies? Finally, how can we rationalize the intestinal immune system as the major focal point for the induction of metabolic syndrome?

In this Review, we discuss some of the most recent advances in intestinal immunometabolism and microbiology in the context of obesity and associated metabolic disease. We also discuss gaps in knowledge and propose avenues of research that might yield new insight into immune cell-microbiota crosstalk and the development of therapeutic modalities.

A pathogenic intestinal immune compartment

Obesity in mice and humans is associated with alterations in the composition of the intestinal immune system (Fig. 1). These shifts are observed in both the adaptive and innate arms of the immune system, which facilitates the emergence of a broadly pro-inflammatory intestinal landscape capable of driving the development of obesity-associated metabolic disease. Here we present an up-to-date summary of obesity-associated alterations to the intestinal immune compartment, focusing on the most recent findings, and provide direction for future research. We further highlight important mechanisms controlling dysfunctional intestinal immune cells that contribute to the development and progression of obesity-associated metabolic disease.

Fig. 1: Obesity alters the intestinal immune compartment.
figure1

A Under lean homeostatic conditions, the intestinal immune environment is dominated by tolerogenic and mucosal barrier maintaining immune cells. These cells include interleukin (IL)-10 producing regulatory T (Treg) cells, IL-22 producing group 3 innate lymphoid cells (ILC3s), and IL-17 secreting protective T helper (Th) 17 cells. Furthermore, under lean conditions, IgA+ antibody-secreting cells (ASCs) are abundant within the lamina propria and produce secretory IgA (SIgA), which interface with the intestinal bacteria. The lean intestinal environment also consists of tolerogenic CX3CR1+ MHC-II+ macrophages and CD103+ CD11b+ dendritic cells (DCs), which have been linked to protective Th17, ILC3, and IgA responses within the intestines. B During diet-induced obesity in mice, there is a shift in the inflammatory potential of the intestinal immune environment, leading to increased numbers of lamina propria Th1 and CD8+ T cells, CD44+ MAIT cells, intestinal homing CCR2+ macrophages, and intestinal intra-epithelial CD8αβ+ T cells, as well as a decrease in the number of the aforementioned tolerogenic cell types. Additionally, small intestine ILC2s have been shown to promote obesity via an IL-2 feedback system, and further work may delineate the basis of this axis. In human subjects with obesity, there is an increase in intestinal CD8αβ+ T cells. These changes result in an inflammatory environment that is linked with intestinal dysfunction, facilitating dysregulated glucose homeostasis during diet-induced obesity.

Aberrant pro-inflammatory shifts in intestinal immune cells during obesity

Cells of the adaptive immune system are critical for an effective response against infectious agents and for the induction of immune memory. In the intestine, these cells are central for mutualism between the host and the intestinal microbiota10. Obesity is associated with important changes to the adaptive immune compartment in the intestines, which results in aberrant inflammatory skewing. In particular, in the intestinal lamina propria, the number of pathogenic interferon-γ (IFN-γ)-producing T helper 1 (Th1) and CD8αβ+ T cells is increased, and the number of protective interleukin 17 (IL-17)-producing Th17 cells and IL-10-secreting regulatory T (Treg) cells is decresaed2,11,12,13 In humans, increased numbers of CD8αβ+ T cells are also detected in the intraepithelial fraction13. T cell classification within the intestine can be further narrowed, and more work is needed to clarify the function of these specific immune cell subsets in obesity. For example, within the intestinal niche, two broad subsets of Treg cells can be separated by the expression of Helios, GATA3, and RORγt14,15. Helios+ GATA3+ Treg cells are of thymic origin, whereas Helios RORγt+ Treg cells differentiate locally in response to the microbiota, are dependent on the transcription factor c-Maf, and are critical in limiting the expansion of Th17 cells15,16. Indeed, T cell subsets in the intestine reflect dynamic responses shaped by the microbiota17. Two distinct subsets of Th17 cells that differ in their metabolic machinery, as well as their inflammatory output, are also present within the intestines18. Homeostatic Th17 cells have a muted inflammatory profile and can be involved in barrier protection, whereas pathogenic Th17 cells secrete large amounts of IFNγ18. These characteristics make it important to discriminate Th17 populations by their cytokine secretion profile, as it is possible that obesity is associated with an overall targeted reduction in homeostatic Th17 cells.

In addition to T cells, intestinal B cells and terminally differentiated antibody-secreting cells (ASCs) have been shown to regulate obesity-associated metabolic disease. Diet-induced obesity is associated with a reduction in intestinal IgA+ ASCs and B cells, which results in a decrease in colonic secretory IgA and contributes to the development of insulin resistance6. Additionally, some ASC subsets, including intestinal IgA+ ASCs, can secrete anti-inflammatory cytokines, such as IL-10, which can dampen local tissue inflammation; however, the effect these cells have in the context of obesity is unclear19. Although B1 and B2 B cells have been examined extensively in the context of regulating adipose tissue inflammation and insulin resistance, little is known about the function of these cell subsets in the intestines in the context of systemic glucose homeostasis20,21.

Under steady-state, cells of the innate immune system are at the forefront in combating pathogens, and although these cells have limited memory responses they are crucial for effective activation and control of adaptive immune cells22. Obesity is associated with several disruptions in the innate intestinal immune compartment, which is subsequently linked with the development of insulin resistance. Notably, the frequency of IL-22 and IL-17-secreting intestinal group 3 innate lymphoid cells (ILC3s) in mice is reduced, an effect that is crucial for maintaining barrier integrity of the intestinal epithelium2. A pathogenic effect of small intestinal group 2 innate lymphoid cells (ILC2s) has also been shown, as mice deficient in these cells are protected from metabolic syndrome23, and adoptively transferring these cells into ILC2-deficient mice can recapitulate parameters of metabolic disease23. Interestingly, during diet-induced obesity in mice, small intestinal ILC2s have been shown to be functionally distinct from adipose tissue ILC2s, as they produce more IL-223, which further preferentially maintains intestinal ILC2s23. However, ILC2s in the intestine is also a prominent source of IL-10, and as such, it is unclear if all of these cells become pathogenic during diet-induced obesity24. In humans, the number of intestinal ILCs has been shown to negatively correlate with BMI, but the functional consequences of this effect are unclear25.

Monocytes, dendritic cells, and macrophages have been implicated in regulating metabolic dysfunction. A CCL2-dependent influx of pro-inflammatory CCR2+ macrophages into the intestines in high fat diet-fed mice is associated with low-grade inflammation and metabolic dysfunction26. Accordingly, the number and activity of CX3CR1+ lamina propria macrophages decreases in high-fat diet-fed mice6,12. Although a reduction in the number of CX3CR1+ macrophages might limit induction of protective Th17 cells and IgA class switch recombination, whether or not an influx of CCR2+ macrophages is directly associated with the loss in CX3CR1 macrophages has not been shown6,12,26. Intestinal monocyte turnover during obesity could be further studied using Tim4 and CD4 as markers, as under steady-state Tim4+ CD4+ macrophages are maintained locally, independent of monocyte contribution, whereas Tim4 CD4+ and Tim4 CD4 are differentially replenished by infiltrating monocytes27. Whether diet-induced obesity is associated with altered macrophage heterogeneity and if such alterations would correlate with obesity-associated intestinal dysfunction is presently unclear. The intestines also maintain a heterogeneous population of dendritic cells that can be categorized into conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs). cDCs can be further subdivided into CD103+ CD11b cDC1s, CD103 CD11b+ cDC2s, and C103+ CD11b+ intestine-specific cDCs28. Although high-fat diet feeding in mice can induce shifts within the cDC compartment, thereby decreasing the abundance of pro-IgA intestinal-specific CD103+ CD11b+ cDCs, thorough functional phenotyping of intestinal DCs during obesity is required6.

Further studies are also needed to characterize changes in intestinal innate-like T cells during obesity-associated metabolic disease. Lipid presentation to NKT cells via CD1d is potentially important for the regulation of intestinal homeostasis29, but whether this homeostatic function is altered during obesity has not been examined. Mucosal-associated invariant T (MAIT) cells are innate-like T cells that recognize bacterial metabolites presented by MR1 and are typically dependent upon exposure to defined microbial communities rich in riboflavin-synthesizing bacteria for development30. MAIT cells produce beneficial IL-17 and can regulate barrier function by attenuating pathogenic intestinal T cell responses31. Obesity in mice is associated with a reduction in the number of MAIT cells in the small intestine, yet those cells that persist have an activated CD44+ phenotype, which contributes to intestinal inflammation and the development of insulin resistance32. Factors that promote this shift in the inflammatory status of MAIT cells during obesity are not identified and require further examination.

Mechanisms for intestinal immune cell promotion of metabolic disease

How changes in the intestinal immune composition during obesity affect systemic parameters of metabolic disease is an important question. In particular, is there a role for intestinal immune cells in contributing to the development of chronic low-grade inflammation at metabolic sites that facilitate insulin resistance, or in the control of hormones that regulate insulin production? Here, we describe a number of important intestinal immune cell-mediated mechanisms that facilitate the development of obesity-associated metabolic tissue inflammation, insulin resistance, intestinal hormone bioavailability, and glucose dysregulation (Fig. 2).

Fig. 2: Mechanisms of intestinal immune cell-driven metabolic dysfunction.
figure2

During obesity, intestinal immune cells contribute to insulin resistance and/or glucose dysregulation, via at least three potential mechanisms. A Changes in immune compartments in the presence of an obesogenic diet promote leakage of bacterial products. This intestinal permeability is facilitated through local changes in cytokines, such as increases in pro-inflammatory cytokines interferon (IFN)γ and tumor-necrosis factor (TNF), coupled with a loss in anti-inflammatory and barrier protective cytokines interleukin (IL)-17, IL-22, and IL-10, anti-microbial peptides (AMPs) and epithelial mucin. Changes in such factors also contribute to the degradation of epithelial tight junction proteins. Increased leakage of bacterial products can drain into metabolic tissues, such as the visceral adipose tissue (VAT) and liver, where they further stimulate local immune cells, such as hepatic Kupffer cells and VAT M1-like macrophages, further enhancing their pro-inflammatory profile and leading to systemic insulin resistance. B Intestinal lymphocytes can potentially sequester gastrointestinal hormones such as glucagon-like peptide (GLP)1, via their GLP1 receptor (GLP1R), thereby limiting its bioavailability and further contributing to metabolic dysfunction. C Finally, evidence indicates that some intestinal immune cells, such as anti-inflammatory IgA+ antibody-secreting cells (ASCs), can potentially migrate to distant inflamed sites in the body, resulting in the reduced intestinal presence of ASC products such as IL-10 and IgA.

Our understanding of the mechanisms by which an altered intestinal immune landscape mediates metabolic dysfunction has previously focused on perturbation of intestinal barrier integrity. During obesity, the pro-inflammatory skewing of immune cells favors the release of cytokines such as TNF and IFNγ, coupled with a reduction in IL-10, IL-17, and IL-22, resulting in reduced expression of epithelial tight junction proteins, mucin, and antimicrobial proteins such as RegIIIγ2,33. This barrier dysfunction has long been hypothesized to be an important driver of metabolic syndrome, as increased levels of bacterial products promote inflammation in important metabolic tissues leading to insulin resistance34. For example, NAFLD and progression to non-alcoholic steatohepatitis (NASH) are, in part, driven by bacterial products (including unmethylated CpG DNA) entering the liver, ultimately activating intra-hepatic Kupffer cells and CD8+ T cells resulting in inflammation, hepatocyte injury and death, insulin resistance with associated increased hepatic gluconeogenesis, and fibrosis35,36. In accordance with these collective findings, treating obese mice with intestinal anti-inflammatory agents, such as 5-aminosalicylic acid, can reduce intestinal permeability and endotoxemia and improve the overall metabolic phenotype2.

Intestinal immune cells further contribute to metabolic disease by regulating the bioavailability of gastrointestinal hormones, which subsequently control blood glucose levels. Under homeostatic conditions, intestinal intraepithelial lymphocytes express the glucagon-like peptide 1 receptor (GLP1R), which, upon signaling, reduces the production of pro-inflammatory cytokines37. Glucagon-like peptide 1 (GLP1) is an incretin that enhances the secretion of insulin to reduce blood glucose levels; during obesity, intestinal epithelial lymphocytes can sequester GLP1 to limit its bioavailability9. Obesity is also associated with a reduction in GLP1-secreting enteroendocrine L cells9, which further contributes to reduced GLP1 levels. In the pro-inflammatory setting of obesity, activated intestinal intraepithelial lymphocytes might also upregulate the expression of molecules (such as dipeptidyl peptidase 4 (DPP4)) that degrade GLP1 as another means to reduce GLP1 bioactivity during obesity38. Chronic exposure of L-cells to TNF can hamper GLP1 production in vitro39, but whether intestinal intraepithelial lymphocyte-derived pro-inflammatory cytokines directly contribute to a loss of L cells in vivo, or potentially modulate levels of other gastrointestinal hormones warrants further investigation. The reciprocal effect of intestinal hormones on local immune cells would also be interesting to explore. For example, cholecystokinin, serotonin, and ghrelin might regulate T cell activation and differentiation of naïve T cells to Th17 and Treg fates40,41,42. Intestinal-derived hormones, as well as neuropeptides, can regulate levels of intestinal IgA and myeloid cell activity, which have altered phenotypes and functionality during obesity43,44. The crosstalk between intestinal endocrine cells and intestinal immune cells is an exciting future direction of research that might uncover mechanisms of intestinal immune cell pathogenicity.

Finally, evidence indicates that some intestinal immune cells can migrate to inflamed metabolic sites45. Under homeostatic conditions, the liver hosts a population of IgA+ ASCs of intestinal origin, which is further expanded during liver disease46. Interestingly, these intestinal ASCs can also access the systemic circulation and migrate to inflamed sites, such as the brain in a mouse model of multiple sclerosis, where they can be immunosuppressive by secreting IL-1019. Similarly, anti-inflammatory effects of hepatic IgA+ ASCs on CD8+ T cells are associated with the progression of hepatocellular carcinoma47. During obesity-associated metabolic disease, intestinal IgA+ ASCs, potentially targeting commensal microorganisms or self-antigens (e.g., through antigenic mimicry), might traffic to inflamed metabolic tissues in an attempt to mitigate inflammation. Such an idea might explain the reduction in their presence in the intestine during diet-induced obesity6. However, this migration away from the intestines would come at the expense of the intestinal barrier, as a lack of these cells could lead to increased intestinal inflammation and intestinal permeability6. Accordingly, accumulation of MAIT cells in the liver during metabolic syndrome has also been documented48, but whether this increase is linked to the loss of these cells due to migration from the small intestine is not clear32.

Expansion of opportunistic microbes

Although intestinal immune cells can contribute to metabolic disease by promoting intestinal barrier dysfunction, altering the bioavailability of gastrointestinal hormones, and migrating to distant sites during disease, these mechanisms are affected by other critical factors, such as crosstalk between obesity-related microbiota and their microbial metabolites. Here, we review alterations to the intestinal microbiota and their metabolome that are linked with the development of obesity-associated metabolic disease.

Bacterial dysbiosis is a hallmark of metabolic syndrome

Obesity is associated with an altered intestinal microbial composition, a state termed dysbiosis. During obesity-related dysbiosis, the intestinal bacterial diversity is reduced and intestinal microbes have enhanced capacity for nutrient harvesting from the diet49. These features have been linked to obesity-associated clinical consequences such as insulin resistance and dyslipidemia49,50. Fecal matter transplant from obese mice and obese human donors into germ-free mice can recapitulate parameters of obesity-associated metabolic dysfunction49,51, providing evidence that intestinal microbes can be pathogenic. Although much work on obesity-associated microbial dysbiosis has explored differences in the ratio of Bacteroidetes to Firmicutes, the metabolic syndrome also seems to be associated with enrichment of Proteobacteria, a phylum that is a potential diagnostic signature of intestinal dysbiosis49,52. For example, an abundance of Proteobacteria correlates with the severity of fibrosis in patients with NAFLD53, and inoculating mice with either the Proteobacteria Enterobacter cloacae54 or Bilophila wadsworthia55 promotes metabolic disease in mice. Such findings implicate Proteobacteria as being involved in the pathogenesis of metabolic syndrome, but the mechanisms that promote the expansion of this opportunistic taxa require further attention. Dietary triggers or metabolites might promote growth, activity and establishment at the expense of commensal bacteria. Alternatively, expansion of Proteobacteria numbers might be a consequence of intestinal inflammation, as can occur in dextran sulfate sodium (DSS) induced colitis in mice56, or due to a loss of neutralizing IgA antibodies6,7. Identifying factors that promote the abundance of opportunistic microbes at the cost of mutualistic commensals should provide a better framework to understand environmental interactions between the host and its microbiome in the context of diet-induced obesity.

Broad interest also exists in replenishing intestinal levels of beneficial microbes, for example with Akkermansia muciniphila of the Verrucomicrobia phylum. Although there is limited evidence for an effect of obesity on the abundance of Akkermansia muciniphilia, oral administration of live and pasteurized microbes, via gavage (mice) and medicinal packages (humans), can improve outcomes associated with metabolic syndrome and liver dysfunction57,58. As the pasteurized form of this bacterium was also effective, it raises the possibility that exposure to high levels of a commensal antigen might have tolerizing effects on intestinal immunity57,58.

Bacterial metabolites affect metabolic disease

Obesity-associated microbial dysbiosis accompanies a change in the presence of important bacterial metabolites, which are now regarded as a means to mediate bacterial effects on the host59. For example, a Western diet is associated with an alteration in microbial fermentation of indigestible carbohydrates, such as dietary fibers, that would typically produce metabolites such as short chain fatty acids (SCFAs) that can inhibit lipogenesis and promote lipid oxidation49,60,61. Fermentation of dietary fibers also produces succinate, which can directly stimulate intestinal gluconeogenesis to improve glucose homeostasis62. Other metabolites that have been identified to mediate beneficial effects and ameliorate obesity-associated metabolic dysfunction include tryptophan-based compounds which signal via the aryl hydrocarbon receptor63 and secondary bile acids that can function through the farnesoid X receptor (FXR)64,65. As an example, bile acids produced in the liver are metabolized by the intestinal microbiome to yield bioactive secondary bile acids66. These bile acids have signaling properties, and interestingly post-bariatric surgery insulin sensitization in individuals with obesity can be mediated by alterations in microbial bile acid metabolite FXR signaling67. How these beneficial microbial metabolites are affected during obesity and how they can be used to improve obesity-related outcomes, is an exciting avenue of future research.

During obesity, there is an upregulation of several pathogenic metabolites, such as trimethylamine, which is enzymatically converted to trimethylalamine N-oxide, an organic compound that is associated with cardiometabolic disease68. Similarly, microbial-produced imidazole propionate, a histidine derivative, has been shown to be elevated in the portal vein of patients with T2D and is capable of impairing insulin signaling at the level of insulin receptor substrate via activation of the mechanistic target of rapamycin complex 1 (mTORC1)69. Intestinal microbe-derived metabolites that affect host physiology have been reviewed elsewhere59. This list will continue to expand in the coming years and should yield further insights into the regulation of metabolic disease.

Pathogenicity of obesogenic intestinal microbes extends to metabolic sites

Evidence indicates that an obesity-associated intestinal microbiota alters important organ-specific metabolic processes in the adipose tissue and liver that ultimately affect systemic insulin resistance and glucose dysregulation. Cells within the adipose tissue can be converted into thermogenic energy dissipating brown-like adipocytes in a process termed beiging, which can be mediated by adipose tissue ILC2s and eosinophils, and has strong insulin-sensitizing effects, yet is compromised during obesity70,71. Versatility in the intestinal microbiome contributes to thermogenesis, as a cold-induced microbiome can promote beiging and insulin sensitization72. Additionally, depletion of the homeostatic commensal microbiome can impair thermogenesis, and amelioration of an obesity-associated microbiome or supplementation with SCFA butyrate can restore thermogenic processes and improve obesity-associated glucose tolerance and insulin sensitivity73,74. Similarly, the intestinal microbiome is crucial to the regulation of hepatic metabolic processes, such as gluconeogenesis and insulin sensitivity, in a manner that is dependent on intestinal metabolite secretion69,75. As such, features of the crosstalk between the intestines, liver and VAT can alter metabolic disease parameters during obesity and are an important area of research that explores the function of microbial metabolites beyond the intestinal tract. Pioneering work has demonstrated that metabolic tissues such as the liver and VAT from individuals who are morbidly obese have unique inter-organ microbial signatures and that tissue-specific taxa differ between individuals with and without T2D76. Importantly, Proteobacteria are highlighted as a predominant phylum within the liver during NAFLD that is associated with lobular and portal inflammation77. Similarly, Proteobacteria is a predominant phylum in the adipose tissue of patients with T2D and can induce local adipose-specific pro-inflammatory responses78. Furthermore, heterogeneity in bacterial composition and abundance can occur between adipose tissue depots, which is further associated with markers of inflammation and insulin resistance78. Interestingly, in patients with T2D, the mesenteric adipose tissue surrounding the intestines has the greatest diversity and number of bacterial operational taxonomical units, suggesting it might function as an initial ‘gatekeeper’ between the intestines and systemic exposure to bacteria during obesity76,78. Cumulatively, these findings suggest that translocation of intact opportunistic microbes from the intestines to metabolic sites might directly alter local tissue immune landscapes, thereby promoting the development of glucose intolerance and insulin resistance in individuals who are obese.

The microbiome–immune cell axis

The crosstalk between intestinal immune cells and microbial species is essential for immune function. Alterations in this crosstalk have been linked with the progression of metabolic disease and are an important emerging area of obesity-related insulin resistance research (Fig. 3), which we discuss in this section.

Fig. 3: Immune-microbiota crosstalk regulates metabolic disease.
figure3

A During obesity, altered intestinal immune cell function is tightly linked with intestinal dysbiosis and a loss in bacterial diversity. Mononuclear phagocytes (MNPs; macrophages and dendritic cells - CX3CR1+ macrophages shown in figure as an example) have an altered ability to produce factors necessary for IgA class switching, such as transforming growth factor-beta (TGF-β), interleukin-5 (IL-5), retinoic acid (RA) via retinaldehyde dehydrogenase (RALDH) enzymes, and a proliferation-inducing ligand (APRIL). This reduction would directly affect the amount and quality of secretory IgA (SIgA) present to bind bacteria, enabling the expansion of opportunistic and pathogenic taxa, such as Proteobacteria, and promoting obesity-associated dysbiosis. Defects in MNP functionality is further affiliated with reduced secretion of factors linked to IgA antibody-secreting cell (ASC) function, and reduced ability to induce T helper 17 (Th17) and regulatory T (Treg) cells. These defects potentially can be further affected by a decreased colony-stimulating factor (Csf)-2 production, as obesity induces a reduction in intestinal group 3 innate lymphoid cells (ILC3s), but this remains to be examined. Simultaneously, pro-inflammatory signaling in intestinal epithelial cells, T cells, and potentially enteric neurons, alters the production of anti-microbial peptides (AMPs), or can directly hinder the beneficial function of beneficial taxa like Akkermansia, contributing to microbial dysbiosis. B The microbiota in turn exert control on immune cells through secretion of metabolites, which are affected by diet-induced obesity. For example, short-chain fatty acids (SCFAs) function through their receptors, such as G-protein coupled receptors (GPRs), to promote levels of intestinal secretory IgA, boost Treg cell responses and promote CX3CR1+ MNP function. Aryl hydrocarbon receptor (AhR) ligands have been associated with increased interleukin (IL)-22 and IL-10 cytokine production, AMP production, and the promotion of epithelial layer mucus and tight junction proteins. Via receptors such as the farnesoid x receptor (FXR) and G-protein coupled bile acid receptor (TGR5), bile acid metabolites might also regulate the intestinal immune landscape through the promotion of Treg cells. These processes are potentially reduced or altered with a Western diet, contributing to inflammatory immunological changes in the intestines during obesity.

Intestinal immune control of the microbiota during obesity

Under homeostatic conditions, IgA is secreted across the intestinal epithelium in its dimeric form as secretory IgA, which binds to bacteria and their products to regulate microbiota composition and reduce microbial penetration across the intestinal barrier79. Reduced levels of secretory IgA in the stool during diet-induced obesity in mice leads to dysbiosis, characterized by increases in the abundance of Proteobacteria and decreases in some Clostridia, coupled with increased intestinal inflammation and reduced intestinal barrier integrity6. Concurrently, during diet-induced obesity in mice, IgA is bound to bacteria at a higher affinity, confirming its ability to bind to pathogenic species6,79. IgA binding can potentially also alter the functionality of obesity-associated microbes, such as global gene expression patterns, affecting their motility and local occupancy within the intestinal environment79. Although the antibody isotype IgM can partially compensate for a loss in IgA in some circumstances, humans with selective IgA deficiency (a form of primary immunodeficiency disease) have an altered intestinal microbiota despite secreting compensatory IgM80,81. Nonetheless, IgM is polyreactive to many bacterial species and whether intestinal production and functionality of this antibody is also altered during metabolic disease has not been examined.

As IgA can be generated via T cell-dependent and T cell-independent mechanisms that control the polyreactivity and affinity of the antibody and which microbes they coat, identifying which pathway is defective during obesity is an important consideration79. T cell-dependent high-affinity IgA production relies on the use of T follicular helper (Tfh) cells, which have been linked with the production of IgA in a diet-induced model of obesity7. Defective Tfh cell function and IgA coating result in a loss of Clostridia and expansion of the Proteobacteria Desulfovibrio population, facilitating dysfunctional lipid metabolism, findings that are in line with studies of IgA-deficient mice6,7.

Although we have a reasonable understanding of defective T cell-dependent IgA production and function during obesity, polyreactive T cell independent IgA requires further study. Under homeostasis, microbial signals induce intestinal ILC3 populations to produce colony-stimulating factor 2 (Csf2), which maintains local mononuclear phagocytes and their ability to express the retinoic acid-generating enzyme retinaldehyde dehydrogenase and secrete TGFβ82. Furthermore, mononuclear phagocytes respond to cues from microbes to modulate their function. This includes orchestrating the production of tertiary lymphoid structures and resultant high-affinity IgA antibodies83, as well as T cell-derived IL-17 and IL-22 responses84. These cellular factors, coupled with secreted factors including IL-5, TGFβ, and a proliferation-inducing ligand (APRIL), support the presence of intestinal IgA and are reduced within the intestinal lamina propria during diet-induced obesity6. Therefore, it might be possible that defective ILC3 and mononuclear phagocyte sensing of the microbiota functions as a mechanism for reduced IgA responses, which in turn regulate the intestinal microbiota during obesity.

Intestinal epithelial cells also confer innate immunity against microbes via their secretion of mucin, anti-microbial peptides, and endocannabinoids85,86. During chronic obesity, aberrant intestinal epithelial cell MyD88 signaling in mice fed a high-fat diet has been linked with the development of obesity-associated insulin resistance, by restricting secretion of endocannabinoids and antimicrobial peptides, and promoting a pro-inflammatory intestinal environment86. Adherence of microbes to intestinal epithelial cells also induces tolerant intestinal Th17 responses87. Future research should study whether obesity interferes with commensal adhesion and associated induction of tolerogenic cytokine responses87.

IFNγ also contributes to microbial control during metabolic disease. IFNγ reduces levels of A. muciniphila by modulating the expression of intestinal Irgm188. As diet-induced obesity is associated with increasing numbers of intestinal IFNγ-expressing T cells, this IFNγ-Irgm1 axis probably constitutes another important means by which immune cells alter bacterial taxa to promote metabolic disease.

Finally, enteric neurons are a source of cytokines that can counter bacterial infections, and affect the production of antimicrobial peptides by intestinal epithelial cells89, but whether or not obesity alters the activity of enteric neurons is not clear.

Microbial metabolites control immune system function during obesity

Just as the immune system exerts control on the intestinal microbiota, the microbiota also affects the composition and function of the immune system, in part through the production of microbial metabolites. SCFAs promote anti-inflammatory T cell responses by enhancing regulatory T cell function and IL-10 secretion90,91. SCFAs also metabolically reprogram B cells to support intestinal antibody responses, such as increasing numbers of IgA+ ASCs and IgA-coating of bacteria92. SCFAs polarize intestinal macrophages to an anti-inflammatory phenotype by increasing oxidative phosphorylation and lipid metabolism and enable mononuclear phagocytes to convert Vitamin A into retinoic acid, thereby promoting the synthesis of intestinal IgA93,94.

Other metabolites, with links to the microbiome, can also trigger GPR responses. For example, succinate can bind GPR91 on dendritic cells, triggering intracellular calcium flux and downstream immune responses95. Lactic acid and pyruvic acid can control the ability of mononuclear phagocytes to extend their dendrites and sample bacterial antigen through GPR3196. Imidazole propionate is a histidine-derived bacterial metabolite that can inhibit insulin signaling at the insulin receptor-substrate level during T2D69. Insulin receptor signaling can stimulate immune cells97; therefore, it would be interesting to see if such metabolites can alter immune cell-intrinsic insulin receptor signaling to affect disease outcomes.

AhR binds endogenous metabolites, dietary components, and microbiota products, and generally promotes the survival and function of intestinal immune cells98. Immune cell-specific activation of the AhR promotes Treg cell secretion of IL-1099, and ILC3 production of IL-22100, as well as regulating B cell class-switching and differentiation into ASCs101. A Western diet is associated with a reduction in intestinal microbial species that generate AhR ligands, which ultimately might lead to the reduced levels of IL-22 that occurs in diet-induced obesity, which can, in turn, reduce intestinal barrier function63. On the other hand, intestinal AhR signaling can also promote intestinal inflammation in some cases. Microbial produced oxazoles can induce AhR signaling on intestinal epithelial cells, which in turn limits CD1d-restricted production of IL-10, thereby activating iNKTs to contribute to intestinal inflammation via IL-13 and IFNγ production102. Indigo, an AhR ligand, which is chemically similar to tryptophan metabolites, can boost immunosuppressive and barrier protective immune responses to alleviate obesity-associated glucose dysregulation and insulin resistance in high-fat diet-fed mice103. However, the effect of AhR binding metabolites on intestinal immune cell function is probably dose-sensitive and thereby requires thorough dose-dependent assessment, as excessive AhR-induced Cyp1a1 production in the intestines can feedback to compromise levels of AhR ligands, resulting in smaller ILC3 and Th17 populations104.

Bile acid receptors FXR and G protein-coupled bile acid receptor 1 (TGR5) have the potential to regulate intestinal inflammation. Bile acid signaling through these receptors increases the anti-inflammatory profile of mononuclear phagocytes cells and T cells105,106. Modulation of intestine-specific FXR signaling via administration of chemical compounds seems to be ligand-specific. In one study, intestinally restricted FXR agonism with oral administration of fexaramine induced fibroblast growth factor 15 and enhanced thermogenesis64. Another study showed that administration of glycine-β-muricholic acid, which preferentially inhibits intestinal FXR, improved metabolic parameters, such as insulin resistance, glucose tolerance, and liver steatosis, by reducing intestinal ceramides107. Interestingly, bile acid metabolites have been shown to be essential for the maintenance of colonic RORγt+ Treg cells and have been linked with controlling intestinal inflammation in a DSS mouse model of colitis108,109. Given the broad effects of intestinal FXR on a variety of cells, understand its effect on the different immune populations within the intestine during obesity is important.

Intestinal immunity in obesity-related therapy

The intestinal immune compartment and microbiota regulate metabolic disease outcomes in a manner that entails crosstalk with one another. Our understanding of this immune cell-microbiota axis has provided new insight into the modes of action of existing therapies as well as in identifying new therapeutic strategies, some of which are discussed in the next section.

Clinical and lifestyle Interventions

The intestinal microbial-immune cell axis is affected by the administration of common therapeutic strategies to treat T2D, such as metformin or bariatric surgery, as well as lifestyle adjustments such as dietary modifications and exercise. Treatment with metformin remodels the microbiota by promoting the growth of glucose-sensitizing Akkermansia muciniphilia and inhibiting the growth of pathogenic Bacteroides fragilis, altering levels of bile acids such as glycoursodeoxycholic acid, and further skewing immune cells to an anti-inflammatory phenotype110,111,112. Bariatric surgery induces long-term changes in the intestinal microbiota and accompanies shifts in bile acid metabolism that are associated with increases in FXR signaling, as well as reductions in inflammation (primarily in VAT) via decreased T cell and macrophage accumulation and inflammatory function113,114. Interestingly, both metformin and bariatric surgery can increase levels of fecal secretory IgA, indicating that they both affect mucosal B cell responses6.

Alterations in diet, eating habits (such as time-restricted eating), and physical activity are at the forefront of lifestyle adjustments in the management of obesity-related insulin resistance. Some microbiota can metabolize polyunsaturated fatty acids to generate metabolites such as 10-hydroxy-cis-12-octadecenoic acid, which can attenuate insulin resistance and inflammation, through activation of GPR40 and GPR120, and GLP-1 secretion115. Administration of a diet high in dietary fibers to patients with T2D promoted the abundance of SCFA-producing microbes and alleviated disease-associated outcomes116, and in mice fed a Western diet, administration of the fiber inulin prevented disease-associated intestinal mucus penetrability and growth defects117. Whether the effects of SCFAs on mucus secretion are mediated by boosting intestinal Treg cell-derived IL-10 is not clear118.

Physiological interventions, such as exercise and caloric restriction, have metabolic benefits, some of which might be mediated by the intestinal microbiota and immune compartment. Exercise can increase the diversity of the microbiota, alter its composition, and attenuate intestinal inflammation119,120. Caloric restriction has also been shown to limit endotoxemia121, and decrease the number of circulating inflammatory monocytes122. Exercise and caloric restriction both have metformin mimicking effects on AMPK signaling and mapping these effects on intestinal immune cells might explain immunological changes within the intestines during such interventions.

Probiotic, synbiotic, and synthetic therapies

A potential strategy to combat metabolic syndrome is the use of probiotic microbes, which are bacteria found in dietary supplements that are thought to have health benefits when consumed; however, the evidence surrounding the efficacy of this method in treating obesity-related insulin resistance is controversial, further complicated by variation in therapeutic effectiveness mediated by bacterial-strain specific effects123. Nonetheless, as demonstrated by the administration of A. muciniphila to individuals with obesity, potentially insulin-sensitizing bacterial species might be administered safely to improve metabolic parameters58. As such, an exciting emerging avenue of work is to utilize unbiased computational screening methods to select microbes that are safe to colonize the host and favorably affect intestinal immune cell tolerogenic function and metabolic homeostasis124. Probiotic approaches can further be supplemented with prebiotics to enable the establishment of beneficial microbial species, a strategy known as “synbiotic therapy”. This method has been shown to be successful in reducing infant systemic inflammation in a randomized, double-blind, placebo-controlled trial to prevent sepsis and associated morbidity125.

Another interesting therapeutic avenue to pursue is the use of genetically engineered microbes. This approach has enabled the development of bacteria that secrete IL-10 to reduce intestinal inflammation126 and has been used as T1D and T2D therapy via administration of GLP1127 or N-acylphosphatidylethanolamine128 secreting synthetic bacteria, to improve glucose homeostasis.

Obesity is associated with compromised oral tolerance; orally fed antigens inhibit immune responses both systemically and locally in the intestines2. In a process that is dependent upon the microbiome, oral antigens are taken up by CX3CR1+ mononuclear phagocytes and transferred to CD103+ dendritic cells to induce anti-inflammatory T cell responses129. As such, the oral administration of beneficial microbes might promote mononuclear phagocyte function and induce intestinal Treg cell responses, enabling the reversal of inflammation in the lamina propria. Whether improved oral tolerance to pasteurized bacterial antigen is partly responsible for improvements in metabolic parameters in patients with obesity who are treated with pasteurized A. muciniphila is not clear.

Finally, an obesity-associated dysbiotic microbiota might be utilized to “vaccinate” individuals, as administration of the intestinal contents of obese mice has been shown to protect against obesity-associated insulin resistance, reduce meta-inflammation and restore the diminished numbers of intestinal Treg cells in mice fed a high-fat diet130. Similarly, immunization of high-fat diet-fed mice with flagellin, a protein highly expressed in some motile inflammatory microbes that can penetrate the mucus layer, decreases intestinal inflammation, increases the abundance of flagellin-specific IgA, and improves overall adiposity131. The precise mechanism responsible for beneficial outcomes of this vaccination strategy is unclear, but probably involves adaptive immune responses, such as via Tfh cells and IgA B cells and ASCs, to generate strong memory responses against pathogenic microbiota130. This vaccination approach also creates the possibility of selecting more specific pathogenic/obesogenic bacterial species or proteins for vaccination to prevent obesity-associated metabolic disease.

Environmental and social factors

Personalized nutrition applies the idea that interindividual variations in intestinal microbiota can control differing metabolic responses to dietary intake132. This interindividual variability also affects the efficacy of probiotic therapy and the host microbiota is central to rendering an individual “resistant” or “permissive” to this approach133. Indeed, after taking antibiotics, probiotics can delay intestinal microbiome reconstitution, whereas autologous fecal matter transplant results in better restoration134.

Evidence indicates that the geography of the host can help to shape personal microbial communities, which can be further narrowed down to a neighborhood level, indicating that host genetics and culture are partly responsible135,136. In line with these observations, geographical migration has been reported to affect the human microbiome. Thai immigrants residing within the USA displayed a loss in native bacterial species and fiber degrading enzymes, which were associated with high body weight (BMI > 25) in immigrant communities137. These findings raise the idea of a corresponding inter-individual intestinal immune system linked to societal-induced changes in the microbiome.

Several factors can alter the intestinal microbiota during early infant life, such as mode of newborn delivery, use of formula feeding or exposure to antibiotics, which might have life-long ramifications for the adult microbiome and intestinal immune system138,139. C-section is associated with colonization of opportunistic bacteria, which could contribute to obesity and associated metabolic outcomes140. Supplying infants with prebiotic-enriched formula might induce SCFA promoting an environment that could protect against intestinal inflammation and obesity141. These ideas highlight the complexity of issues needed for efficient personalized nutrition.

Working model

We propose a multi-hit hypothesis that controls the crosstalk between the host microbiome and immune system in regulating obesity-associated metabolic outcomes (Fig. 4). Initially, an interface between the host microbiome and immune system is achieved at birth, where microorganisms from the environment establish symbiosis with newborns138. In humans, the first 3 months of life are a critical period for the stereotypic development of immune cells, which is perturbed in infants experiencing microbial dysbiosis139. Accordingly, germ-free mice have defects in the relative abundance of important intestinal immune cells required for mutualism (i.e., symbiosis) with intestinal commensal microbes, such as CD4+ T cells and IgA+ ASCs142,143. Early-life microbial dysbiosis as a consequence of the environmental variables discussed in this Review, such as host genetics, mode of delivery, host geography and antibiotic usage, potentially act as a trigger that affects intestinal immune cell function and potentially increases susceptibility to obesity-associated meta-inflammation.

Fig. 4: A working model of intestinal-driven metabolic disease.
figure4

We propose that early life factors induce microbial dysbiosis, which can extend to adult life and potentiate the microbiome towards an obesogenic phenotype. Consumption of a Western diet results in a dietary trigger that further establishes pro-obesity intestinal microbial dysbiosis and a shift in the intestinal immune landscape towards a pro-inflammatory phenotype with limited intestinal IgA responses. Intestinal immune changes are also poised to alter intestinal hormone bioavailability. Low-grade inflammation coupled with dietary factors promotes intestinal permeability and facilitates the leakage of microbial ligands systemically. Consequently, penetration of microbial antigens and colonization of microbes at metabolic sites, such as the liver and visceral adipose tissue (VAT), affects tissue-specific metabolic processes and tissue-specific immune cell functionality. These processes are consistently affected by interactions between the host environment and genetics, ultimately resulting in the development of metabolic complications such as insulin resistance and non-alcoholic fatty liver disease.

Western diets that are rich in saturated fats, red meat, and sugars, while lacking in dietary fibers and vegetables, are a major risk factor that contributes to the development of obesity144. The consumption of a Western diet is the second key interaction that affects the host microbiota-immune cell axis and alters microbial composition from early infancy to adulthood. For example, diets rich in fats result in an over-representation of pathogenic LPS-expressing bacteria and subsequent metabolic endotoxemia34. The type of fat in the diet is also important. Compared with mice fed a diet high in unsaturated fats, mice provided with a diet high in saturated fats acquire a distinct intestinal microbiota composition that directly promotes pro-inflammatory processes via TLR-MyD88 signaling145. This change in fat intake might also affect the type of secondary bile acids produced by intestinal microbes. Similarly, excessive intake of dietary sugars, such as fructose and glucose, is associated with intestinal microbial dysbiosis and an increase in the abundance of opportunistic Proteobacteria at the phylum level146,147. Excessive intake of red meat results in increased microbial metabolism of dietary l-carnitine and trimethylalamine N-oxide production, which promote cholesterol accumulation and the pro-inflammatory output of macrophages148. Concurrently, removal of vegetables from the diet would diminish the supply of dietary fiber necessary for the production of SCFAs, herbal metabolites required for AhR activation, and Vitamin A essential for the generation of retinoic acid and IgA149,150,151. Therefore, the Western diet equips microbiota with the tools necessary to counter a tolerogenic immune system. These changes to the intestinal immune system also skew it away from reparative programs and have the capacity to disrupt the intestinal barrier98.

Third, hyperglycemia as a consequence of a Western diet facilitates intestinal epithelial cell reprogramming and reinforces a loss in intestinal barrier integrity, increasing penetration of immune stimulatory microbial ligands into the basal portion of intestinal epithelial cells, the lamina propria, and vasculature152. This leakage of microbial products further promotes a cascade of pro-inflammatory events in the local intestinal immune landscape, resulting in increases in pro-inflammatory cytokines, and decreases in tolerogenic anti-inflammatory cytokines and IgA antibodies. A shift toward pro-inflammatory cytokine production can disrupt tight junction proteins and negatively affect some commensal microbes, such as through the IFNγ–Irgm1 axis88. Concurrently a loss in neutralizing IgA antibodies further facilitates an increased expansion of opportunistic microbes and associated penetration of pathogenic microbial products, thereby establishing a positive feedback loop6,7.

Drainage of microbial products and bacterial communities into metabolic tissues, such as the VAT and liver, results in reprogramming of tissue-specific inflammatory cells, associated with an expansion and recruitment of pro-inflammatory immune cells and a loss in tissue-resident tolerogenic immune cells98. In the VAT, these processes can potentially facilitate a loss in thermogenic properties, the formation of crown-like structures, and altered adipokine secretion4. In the liver, this process contributes to progression of NAFLD and transition to NASH, categorized by liver steatosis, hepatocyte degeneration, hepatic insulin resistance and the onset of hepatic fibrosis3. Though compensatory immune mechanisms at metabolic tissues are initiated, such as the emergence of Trem2+ macrophages, that regulate lipid homeostasis in adipose tissue153, and anti-inflammatory IgA ASCs that are possibly of intestinal origin47, we hypothesize that these mechanisms are probably not sufficient for preventing the development of obesity-related metabolic disease. Cumulatively, these effects can trigger a chronic systemic pro-inflammatory response and establish obesity-associated metabolic disease.

Conclusion

Although major advances have been made in the field of obesity-associated intestinal immunometabolism, future work should continue building our understanding of the immune cell-microbiota axis, which fundamentally affects the outcomes associated with metabolic syndrome. Moving forward, it is essential to incorporate large scale analyses that better dissect these relations, such as imaging mass cytometry to visualize the immune landscape paired with single-cell RNA sequencing to obtain transcriptional profiles and facilitate the discovery of diet-induced metabolic changes to intestinal immune phenotypes, activation pathways, antigen receptor diversity, and even predict developmental lineages and cellular dynamics within the intestines of individuals who are obese.

Similarly, studies should further conduct unbiased large-scale omics analyses on the intestinal bacteria as well as their metabolome to identify important microbes and metabolites that can be targeted or boosted to ameliorate metabolic syndrome. The microbiota associated with obesity and the systemic metabolome should also be screened against specific receptors, as has been done for GPCRs under healthy steady-state conditions, which will identify diet–microbe–host axes that are altered between individuals who are obese versus lean154. Importantly, a consideration for experimental models and controls needs to be made when assessing a role for the intestinal microbiome in health and disease. When assessing mice with genetic differences, littermate breeding strategies should be incorporated to standardize the microbiota and limit incorrect conclusions155. Additionally, germ-free mice have perturbations in the generation and function of many immune cells, which confounds their use as tools to identify the causal role of microbes via fecal matter transplants or administration of enriched or purified bacterial communities. Nonetheless, assessing the microbial metabolome in inoculated germ-free recipients can yield mechanistic insights and provide a starting point for screening immune cell function in vivo against metabolites of interest. Furthermore, the intestinal microbiota includes an array of organisms other than bacteria, such as viruses, fungi, bacteriophages, and protists, which might be implicated in the progression of metabolic disease. Further investigation is needed to understand how these organisms might affect the bacterial microbiota and immune cells.

Understanding intestinal immune cell signaling axes and crosstalk with intestinal microbes is important for the identification of therapeutic targets to treat obesity and metabolic syndrome. With future research adding to our understanding of obesity-associated intestinal dysfunction and uncovering mechanisms of immune cell pathogenicity, we will be closer to the goal of developing safe therapies with improved effectiveness in obesity-related metabolic disease.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

References

  1. 1.

    González-Muniesa, P. et al. Obesity. Nat. Rev. Dis. Prim. 3, 17034 (2017).

    PubMed  Article  PubMed Central  Google Scholar 

  2. 2.

    Luck, H. et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab. 21, 527–542 (2015). Low level gut inflammation is directly linked with reduced intestinal permeability and oral tolerance during diet-induced obesity, which can be alleviated upon treatment with intestinal anti-inflammatory agents.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Schuster, S., Cabrera, D., Arrese, M. & Feldstein, A. E. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349–364 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  4. 4.

    Khan, S., Chan, Y. T., Revelo, X. S. & Winer, D. A. The immune landscape of visceral adipose tissue during obesity and aging. Front. Endocrinol. 11, 267 (2020).

    Article  Google Scholar 

  5. 5.

    Winer, D. A., Luck, H., Tsai, S. & Winer, S. The intestinal immune system in obesity and insulin resistance. Cell Metab. 23, 413–426 (2016).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Luck, H. et al. Gut-associated IgA+ immune cells regulate obesity-related insulin resistance. Nat. Commun. 10, 3650 (2019). Obesity compromises synthesis of intestinal IgA antibodies that have a critical function in controlling the expansion of pathogenic microbes during metabolic disease.

    ADS  PubMed  PubMed Central  Article  CAS  Google Scholar 

  7. 7.

    Petersen C. et al. T cell-mediated regulation of the microbiota protects against obesity. Science 365, eaat9351 (2019). T cell dependent synthesis of intestinal IgA is critical in preventing the formation of an obesogenic microbiota to regulate host lipid absorption.

  8. 8.

    Tilg H., Zmora N., Adolph T. E. & Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat. Rev. Immunol. 40–54 (2019).

  9. 9.

    He, S. et al. Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease. Nature 566, 115–119 (2019). Intraepithelial lymphocytes modulate enteroendocrine activity and are metabolically hyperactive during obesity, resulting in limited bioavailability of GLP-1.

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Feng, T. & Elson, C. O. Adaptive immunity in the host-microbiota dialog. Mucosal Immunol. 4, 15–21 (2011).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Garidou, L. et al. The gut microbiota regulates intestinal CD4 T cells expressing RORγt and controls metabolic disease. Cell Metab. 22, 100–112 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  12. 12.

    Hong, C. P. et al. Gut-specific delivery of T-helper 17 cells reduces obesity and insulin resistance in mice. Gastroenterology 152, 1998–2010 (2017). Obesity compromises intestinal Th17 populations, re-introduction of which promotes expansion of microbes associated with metabolic homeostasis.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Monteiro-Sepulveda, M. et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. Cell Metab. 22, 113–124 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  14. 14.

    Sefik, E. et al. Individual intestinal symbionts induce a distinct population of RORγ+ regulatory T cells. Science 349, 993–997 (2015).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Xu, M. et al. c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature 554, 373–377 (2018).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Neumann, C. et al. C-Maf dependent Treg cells control of intestinal Th17 cells and IgA establishes host-microbiota homeostasis. Nat. Immunol. 20, 471–481 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    Kiner, E. et al. Gut CD4(+) T cell phenotypes are a continuum molded by microbes, not by TH archetypes. Nat. Immunol. 22, 216–228 (2021).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  18. 18.

    Omenetti, S. et al. The intestine harbors functionally distinct homeostatic tissue-resident and inflammatory Th17 cells. Immunity 51, 77–89.e76 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Rojas, O. L. et al. Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10. Cell 176, 610–624.e618 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Winer, D. A. et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 17, 610–617 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Shen, L. et al. B-1a lymphocytes attenuate insulin resistance. Diabetes 64, 593–603 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  22. 22.

    Kinnebrew, M. A. & Pamer, E. G. Innate immune signaling in defense against intestinal microbes. Immunol. Rev. 245, 113–131 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Sasaki, T. et al. Innate lymphoid cells in the induction of obesity. Cell Rep. 28, 202–217.e207 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  24. 24.

    Bando J. K. et al. ILC2s are the predominant source of intestinal ILC-derived IL-10. J. Exp. Med. 217, e20191520 (2020).

  25. 25.

    Yudanin, N. A. et al. Spatial and temporal mapping of human innate lymphoid cells reveals elements of tissue specificity. Immunity 50, 505–519.e504 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Kawano, Y. et al. Colonic pro-inflammatory macrophages cause insulin resistance in an intestinal Ccl2/Ccr2-dependent manner. Cell Metab. 24, 295–310 (2016). Pro-inflammatory macrophages infiltrate the lamina propria early during high-fat diet feeding thereby initiating intestinal driven metabolic disease.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Shaw, T. N. et al. Tissue-resident macrophages in the intestine are long lived and defined by Tim-4 and CD4 expression. J. Exp. Med. 215, 1507–1518 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Stagg, A. J. Intestinal dendritic cells in health and gut inflammation. Front. Immunol. 9, 2883 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Sáez de Guinoa J. et al. CD1d-mediated lipid presentation by CD11c+ cells regulates intestinal homeostasis. EMBO J. 37, e97537 (2018).

  30. 30.

    Constantinides M. G. et al. MAIT cells are imprinted by the microbiota in early life and promote tissue repair. Science 366, eaax6624 (2019).

  31. 31.

    Varelias, A. et al. Recipient mucosal-associated invariant T cells control GVHD within the colon. J. Clin. Investig. 128, 1919–1936 (2018).

    PubMed  Article  PubMed Central  Google Scholar 

  32. 32.

    Toubal, A. et al. Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity. Nat. Commun. 11, 3755 (2020).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Wang, X. et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 514, 237–241 (2014).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  34. 34.

    Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772 (2007). Bacterial products leaking via the intestinal barrier initiate the development of obesity associated metabolic disease.

    CAS  Article  Google Scholar 

  35. 35.

    Ghazarian M. et al. Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Sci. Immunol. 2, eaai7616 (2017).

  36. 36.

    Imajo, K. et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 16, 44–54 (2012).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Yusta, B. et al. GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R. Diabetes 64, 2537–2549 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Tsai, S., Winer, S., Winer, D. A. & Gut, T. Cells feast on GLP-1 to modulate cardiometabolic disease. Cell Metab. 29, 787–789 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  39. 39.

    Gagnon, J. et al. Chronic exposure to TNFα impairs secretion of glucagon-like peptide-1. Endocrinology 156, 3950–3960 (2015).

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Xu, Y. et al. Ghrelin inhibits the differentiation of T helper 17 cells through mTOR/STAT3 signaling pathway. PLoS ONE 10, e0117081 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  41. 41.

    Zhang, J. G. et al. Cholecystokinin octapeptide regulates the differentiation and effector cytokine production of CD4(+) T cells in vitro. Int. Immunopharmacol. 20, 307–315 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  42. 42.

    León-Ponte, M., Ahern, G. P. & O’Connell, P. J. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood 109, 3139–3146 (2007).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  43. 43.

    Keith Hanna, M. et al. Individual neuropeptides regulate gut-associated lymphoid tissue integrity, intestinal immunoglobulin A levels, and respiratory antibacterial immunity. J. Parenter. Enter. Nutr. 24, 261–268 (2000). discussion 268–269.

    CAS  Article  Google Scholar 

  44. 44.

    Miyamoto, S. et al. Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin. Diabetes 61, 897–907 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Morton, A. M. et al. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. Proc. Natl Acad. Sci. USA 111, 6696–6701 (2014).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  46. 46.

    Moro-Sibilot, L. et al. Mouse and human liver contain immunoglobulin A-secreting cells originating from Peyer’s patches and directed against intestinal antigens. Gastroenterology 151, 311–323 (2016).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  47. 47.

    Shalapour, S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551, 340–345 (2017).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Li, Y. et al. Mucosal-associated invariant T cells improve nonalcoholic fatty liver disease through regulating macrophage polarization. Front. Immunol. 9, 1994 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  49. 49.

    Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006). Obesity is associated with shifts in the relative abundance of bacterial phyla and communities; germ-free animals can be colonized with donor microbes to ascertain microbial causality.

    ADS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541–546 (2013).

    PubMed  Article  CAS  Google Scholar 

  51. 51.

    Ridaura, V. K. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013).

    PubMed  Article  CAS  Google Scholar 

  52. 52.

    Shin, N. R., Whon, T. W. & Bae, J. W. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 33, 496–503 (2015).

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Loomba, R. et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 25, 1054–1062.e1055 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Fei, N. & Zhao, L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J. 7, 880–884 (2013).

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Natividad, J. M. et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat. Commun. 9, 2802 (2018).

    ADS  PubMed  PubMed Central  Article  CAS  Google Scholar 

  56. 56.

    Winter, S. E. et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 339, 708–711 (2013).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107–113 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  58. 58.

    Depommier, C. et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat. Med. 25, 1096–1103 (2019). Pasteurized tolerogenic microbe Akkermansia muciniphila can be administered safely to human patients to clinically improve metabolic disease parameters.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Canfora, E. E., Meex, R. C. R., Venema, K. & Blaak, E. E. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat. Rev. Endocrinol. 15, 261–273 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  60. 60.

    Schwiertz, A. et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 18, 190–195 (2010).

    PubMed  Article  PubMed Central  Google Scholar 

  61. 61.

    den Besten, G. et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes 64, 2398–2408 (2015).

    Article  CAS  Google Scholar 

  62. 62.

    De Vadder, F. et al. Microbiota-produced succinate improves glucose homeostasis via intestinal gluconeogenesis. Cell Metab. 24, 151–157 (2016).

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  63. 63.

    Natividad, J. M. et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab. 28, 737–749.e734 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  64. 64.

    Fang, S. et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159–165 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Wang, K. et al. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Rep. 26, 222–235.e225 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  66. 66.

    Jia, W. & Xie, G. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15, 111–128 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  67. 67.

    Wahlström, A., Sayin, S. I., Marschall, H. U. & Bäckhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 (2016).

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  68. 68.

    Schugar, R. C. et al. The TMAO-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue. Cell Rep. 19, 2451–2461 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Koh, A. et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell 175, 947–961.e917 (2018). Microbial metabolites can affect host physiological functions to promote insulin resistance.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  70. 70.

    Brestoff, J. R. et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519, 242–246 (2015).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  71. 71.

    Qiu, Y. et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 157, 1292–1308 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  72. 72.

    Chevalier, C. et al. Gut microbiota orchestrates energy homeostasis during cold. Cell 163, 1360–1374 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  73. 73.

    Suárez-Zamorano, N. et al. Microbiota depletion promotes browning of white adipose tissue and reduces obesity. Nat. Med. 21, 1497–1501 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  74. 74.

    Li, B. et al. Microbiota depletion impairs thermogenesis of brown adipose tissue and browning of white adipose tissue. Cell Rep. 26, 2720–2737.e2725 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  75. 75.

    Krisko, T. I. et al. Dissociation of adaptive thermogenesis from glucose homeostasis in microbiome-deficient mice. Cell Metab. 31, 592–604.e599 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Anhê, F. et al. Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity. Nat. Metab. 2, 233–242 (2020). Microbes can translocate to metabolic sites during obesity and possess a unique signature, thereby representing targets and biomarkers for type 2 diabetes.

    PubMed  Article  PubMed Central  Google Scholar 

  77. 77.

    Sookoian, S. et al. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 69, 1483–1491 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  78. 78.

    Massier, L. et al. Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes. Gut 69, 1796–1806 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  79. 79.

    Bunker, J. J. & Bendelac, A. IgA responses to microbiota. Immunity 49, 211–224 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  80. 80.

    Fadlallah J. et al. Microbial ecology perturbation in human IgA deficiency. Sci. Transl. Med. 10, eaan1217 (2018).

  81. 81.

    Catanzaro, J. R. et al. IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM. Sci. Rep. 9, 13574 (2019).

    ADS  PubMed  PubMed Central  Article  CAS  Google Scholar 

  82. 82.

    Mortha, A. et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343, 1249288 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  83. 83.

    Koscsó B. et al. Gut-resident CX3CR1 hi macrophages induce tertiary lymphoid structures and IgA response in situ. Sci. Immunol. 5, eaax0062 (2020).

  84. 84.

    Martínez-López, M. et al. Microbiota sensing by mincle-syk axis in dendritic cells regulates interleukin-17 and -22 production and promotes intestinal barrier integrity. Immunity 50, 446–461.e449 (2019).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  85. 85.

    Allaire, J. M. et al. The intestinal epithelium: central coordinator of mucosal immunity. Trends Immunol. 39, 677–696 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  86. 86.

    Everard, A. et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat. Commun. 5, 5648 (2014).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  87. 87.

    Atarashi, K. et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 163, 367–380 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  88. 88.

    Greer, R. L. et al. Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism. Nat. Commun. 7, 13329 (2016).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  89. 89.

    Jarret, A. et al. Enteric nervous system-derived IL-18 orchestrates mucosal barrier immunity. Cell 180, 50–63.e12 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  91. 91.

    Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  92. 92.

    Kim, M., Qie, Y., Park, J. & Kim, C. H. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe 20, 202–214 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  93. 93.

    Wu, W. et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal Immunol. 10, 946–956 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  94. 94.

    Scott N. A. et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci. Transl. Med. 10, eaao4755 (2018).

  95. 95.

    Rubic, T. et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat. Immunol. 9, 1261–1269 (2008).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  96. 96.

    Morita, N. et al. GPR31-dependent dendrite protrusion of intestinal CX3CR1+ cells by bacterial metabolites. Nature 566, 110–114 (2019).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  97. 97.

    Tsai, S. et al. Insulin Receptor-Mediated Stimulation Boosts T Cell Immunity during Inflammation and Infection. Cell Metab. 28, 922–934.e924 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  98. 98.

    Winer, D. A., Winer, S., Dranse, H. J. & Lam, T. K. Immunologic impact of the intestine in metabolic disease. J. Clin. Investig. 127, 33–42 (2017).

    PubMed  Article  PubMed Central  Google Scholar 

  99. 99.

    Goettel, J. A. et al. AHR activation is protective against colitis driven by T cells in humanized mice. Cell Rep. 17, 1318–1329 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  100. 100.

    Qiu, J. et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 39, 386–399 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  101. 101.

    Vaidyanathan, B. et al. The aryl hydrocarbon receptor controls cell-fate decisions in B cells. J. Exp. Med. 214, 197–208 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  102. 102.

    Iyer, S. S. et al. Dietary and Microbial Oxazoles Induce Intestinal Inflammation by Modulating Aryl Hydrocarbon Receptor Responses. Cell 173, 1123–1134.e1111 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. 103.

    Lin Y. H. et al. Aryl hydrocarbon receptor agonist indigo protects against obesity-related insulin resistance through modulation of intestinal and metabolic tissue immunity. Int. J. Obes. 2407–2421 (2019).

  104. 104.

    Schiering, C. et al. Feedback control of AHR signalling regulates intestinal immunity. Nature 542, 242–245 (2017).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  105. 105.

    Cao, W. et al. The xenobiotic transporter Mdr1 enforces T cell homeostasis in the presence of intestinal bile acids. Immunity 47, 1182–1196.e1110 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  106. 106.

    Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183, 6251–6261 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  107. 107.

    Jiang, C. et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  108. 108.

    Song, X. et al. Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis. Nature 577, 410–415 (2019).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  109. 109.

    Hang, S. et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature 576, 143–148 (2019).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  110. 110.

    Sun, L. et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 24, 1919–1929 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  111. 111.

    Shin, N. R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  112. 112.

    Jing, Y. et al. Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol. Cell Endocrinol. 461, 256–264 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  113. 113.

    Cancello, R. et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54, 2277–2286 (2005).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  114. 114.

    Tremaroli, V. et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 22, 228–238 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  115. 115.

    Miyamoto, J. et al. Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nat. Commun. 10, 4007 (2019).

    ADS  PubMed  PubMed Central  Article  CAS  Google Scholar 

  116. 116.

    Zhao, L. et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 359, 1151–1156 (2018). Dietary fibers can be consumed to boost short chain fatty acid producing microbes to clinically improve metabolic disease outcomes.

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  117. 117.

    Schroeder, B. O. et al. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe 23, 27–40.e27 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  118. 118.

    Hasnain, S. Z. et al. IL-10 promotes production of intestinal mucus by suppressing protein misfolding and endoplasmic reticulum stress in goblet cells. Gastroenterology 144, 357–368.e359 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  119. 119.

    Kern T. et al. Structured exercise alters the gut microbiota in humans with overweight and obesity—a randomized controlled trial. Int. J. Obes. 125–135 (2019).

  120. 120.

    Gleeson, M. et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. 11, 607–615 (2011).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  121. 121.

    Fabbiano, S. et al. Functional gut microbiota remodeling contributes to the caloric restriction-induced metabolic improvements. Cell Metab. 28, 907–921.e907 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  122. 122.

    Jordan, S. et al. Dietary intake regulates the circulating inflammatory monocyte pool. Cell 178, 1102–1114.e1117 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  123. 123.

    Rondanelli, M. et al. Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. Gut Microbes 8, 521–543 (2017).

    PubMed  PubMed Central  Article  Google Scholar 

  124. 124.

    Stein R. R., et al. Computer-guided design of optimal microbial consortia for immune system modulation. Elife 7, e30916 (2018).

  125. 125.

    Panigrahi, P. et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature 548, 407–412 (2017).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  126. 126.

    Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352–1355 (2000).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  127. 127.

    Duan, F. F., Liu, J. H. & March, J. C. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 64, 1794–1803 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  128. 128.

    Chen, Z. et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J. Clin. Investig. 124, 3391–3406 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  129. 129.

    Mazzini, E., Massimiliano, L., Penna, G. & Rescigno, M. Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1+ macrophages to CD103+ dendritic cells. Immunity 40, 248–261 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  130. 130.

    Pomié, C. et al. Triggering the adaptive immune system with commensal gut bacteria protects against insulin resistance and dysglycemia. Mol. Metab. 5, 392–403 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  131. 131.

    Tran, H. Q., Ley, R. E., Gewirtz, A. T. & Chassaing, B. Flagellin-elicited adaptive immunity suppresses flagellated microbiota and vaccinates against chronic inflammatory diseases. Nat. Commun. 10, 5650 (2019).

    ADS  PubMed  PubMed Central  Article  CAS  Google Scholar 

  132. 132.

    Zeevi, D. et al. Personalized nutrition by prediction of glycemic responses. Cell 163, 1079–1094 (2015).

    CAS  PubMed  Article  Google Scholar 

  133. 133.

    Zmora, N. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174, 1388–1405.e1321 (2018). Individual humans have specific resistance to probiotics, which can be predicted by pre-treatment microbiome and host features, thereby warranting the use of a personalized medicine.

    CAS  PubMed  Article  Google Scholar 

  134. 134.

    Suez, J. et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 174, 1406–1423.e1416 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  135. 135.

    He, Y. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat. Med. 24, 1532–1535 (2018).

    CAS  PubMed  Article  Google Scholar 

  136. 136.

    Deschasaux, M. et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat. Med. 24, 1526–1531 (2018).

    CAS  PubMed  Article  Google Scholar 

  137. 137.

    Vangay, P. et al. US immigration westernizes the human gut microbiome. Cell 175, 962–972.e910 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  138. 138.

    Bokulich, N. A. et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. Sci. Transl. Med. 8, 343ra382 (2016).

    Article  CAS  Google Scholar 

  139. 139.

    Olin, A. et al. Stereotypic immune system development in newborn children. Cell 174, 1277–1292.e1214 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  140. 140.

    Shao, Y. et al. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. Nature 574, 117–121 (2019).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  141. 141.

    Baumann-Dudenhoeffer, A. M., D’Souza, A. W., Tarr, P. I., Warner, B. B. & Dantas, G. Infant diet and maternal gestational weight gain predict early metabolic maturation of gut microbiomes. Nat. Med. 24, 1822–1829 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  142. 142.

    Mazmanian, S. K., Liu, C. H., Tzianabos, A. O. & Kasper, D. L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122, 107–118 (2005).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  143. 143.

    Fritz, J. H. et al. Acquisition of a multifunctional IgA+ plasma cell phenotype in the gut. Nature 481, 199–203 (2011).

    ADS  PubMed  PubMed Central  Article  CAS  Google Scholar 

  144. 144.

    Kopp, W. How western diet and lifestyle drive the pandemic of obesity and civilization diseases. Diabetes Metab. Syndr. Obes. 12, 2221–2236 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  145. 145.

    Caesar, R., Tremaroli, V., Kovatcheva-Datchary, P., Cani, P. D. & Bäckhed, F. Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling. Cell Metab. 22, 658–668 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  146. 146.

    Do M. H., Lee E., Oh M. J., Kim Y., Park H. Y. High-glucose or -fructose diet cause changes of the gut microbiota and metabolic disorders in mice without body weight change. Nutrients 10 (2018).

  147. 147.

    Khan S. et al. Dietary simple sugars alter microbial ecology in the gut and promote colitis in mice. Sci. Transl. Med. 12, eaay6218 (2020).

  148. 148.

    Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med 19, 576–585 (2013).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  149. 149.

    Samuel, B. S. et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl Acad. Sci. USA 105, 16767–16772 (2008).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  150. 150.

    Jeuken, A. et al. Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits. J. Agric. Food Chem. 51, 5478–5487 (2003).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  151. 151.

    Ross, A. C., Chen, Q. & Ma, Y. Vitamin A and retinoic acid in the regulation of B-cell development and antibody production. Vitam. Horm. 86, 103–126 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  152. 152.

    Thaiss, C. A. et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science 359, 1376–1383 (2018). Hyperglycemia directly contributes to reduced intestinal barrier function, thereby positing glucose as an initial trigger for intestinal-driven metabolic disease.

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  153. 153.

    Deczkowska, A., Weiner, A. & Amit, I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell 181, 1207–1217 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  154. 154.

    Chen, H. et al. A forward chemical genetic screen reveals gut microbiota metabolites that modulate host physiology. Cell 177, 1217–1231.e1218 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  155. 155.

    Robertson, S. J. et al. Comparison of co-housing and littermate methods for microbiota standardization in mouse models. Cell Rep. 27, 1910–1919.e1912 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

Download references

Acknowledgements

S.K. is a recipient of the Ontario Graduate Scholarship (OGS), and the Banting & Best Center (BBDC)—University Health Network Graduate Award. D.A.W. is funded by a Canadian Institutes of Health Research (CIHR) New Investigator Foundation Grant FDN-148385 (D.A.W.) and a Canadian Liver Foundation operating grant (2017). D.A.W. holds an Ontario Ministry of Innovation Early Researcher Award.

Author information

Affiliations

Authors

Contributions

S.K., H.L., S.W., and D.A.W. contributed to the design and writing of the paper and the generation of the figures.

Corresponding author

Correspondence to Daniel A. Winer.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information Nature Communications thanks Shannon Reilly and the other, anonymous reviewer(s) for their contribution to the peer review of this work. Peer review reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Khan, S., Luck, H., Winer, S. et al. Emerging concepts in intestinal immune control of obesity-related metabolic disease. Nat Commun 12, 2598 (2021). https://doi.org/10.1038/s41467-021-22727-7

Download citation

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing